DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Remdesivir |
DMBFZ6L
|
Moderate |
Increased risk of hepatotoxicity by the combination of Interferon Alfa-2a, Recombinant and Remdesivir. |
1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]
|
[3] |
Thioguanine |
DM7NKEV
|
Moderate |
Increased risk of hepatotoxicity by the combination of Interferon Alfa-2a, Recombinant and Thioguanine. |
Acute myeloid leukaemia [2A60]
|
[4] |
Bedaquiline |
DM3906J
|
Moderate |
Increased risk of hepatotoxicity by the combination of Interferon Alfa-2a, Recombinant and Bedaquiline. |
Antimicrobial drug resistance [MG50-MG52]
|
[5] |
Aminophylline |
DML2NIB
|
Moderate |
Decreased metabolism of Interferon Alfa-2a, Recombinant caused by Aminophylline mediated inhibition of CYP450 enzyme. |
Asthma [CA23]
|
[6] |
Roflumilast |
DMPGHY8
|
Moderate |
Additive immunosuppressive effects by the combination of Interferon Alfa-2a, Recombinant and Roflumilast. |
Asthma [CA23]
|
[7] |
Pexidartinib |
DMS2J0Z
|
Major |
Increased risk of hepatotoxicity by the combination of Interferon Alfa-2a, Recombinant and Pexidartinib. |
Bone/articular cartilage neoplasm [2F7B]
|
[8] |
PMID27977313-Compound-29 |
DMIF7KG
|
Moderate |
Increased risk of hepatotoxicity by the combination of Interferon Alfa-2a, Recombinant and PMID27977313-Compound-29. |
Discovery agent [N.A.]
|
[9] |
PMID28870136-Compound-48 |
DMPIM9L
|
Moderate |
Decreased metabolism of Interferon Alfa-2a, Recombinant caused by PMID28870136-Compound-48 mediated inhibition of CYP450 enzyme. |
Discovery agent [N.A.]
|
[6] |
Cannabidiol |
DM0659E
|
Moderate |
Increased risk of hepatotoxicity by the combination of Interferon Alfa-2a, Recombinant and Cannabidiol. |
Epileptic encephalopathy [8A62]
|
[7] |
Brentuximab vedotin |
DMWLC57
|
Moderate |
Increased risk of hepatotoxicity by the combination of Interferon Alfa-2a, Recombinant and Brentuximab vedotin. |
Hodgkin lymphoma [2B30]
|
[10] |
Efavirenz |
DMC0GSJ
|
Moderate |
Increased risk of hepatotoxicity by the combination of Interferon Alfa-2a, Recombinant and Efavirenz. |
Human immunodeficiency virus disease [1C60-1C62]
|
[11] |
Zalcitabine |
DMH7MUV
|
Moderate |
Increased risk of peripheral neuropathy by the combination of Interferon Alfa-2a, Recombinant and Zalcitabine. |
Human immunodeficiency virus disease [1C60-1C62]
|
[12] |
Mipomersen |
DMGSRN1
|
Major |
Increased risk of hepatotoxicity by the combination of Interferon Alfa-2a, Recombinant and Mipomersen. |
Hyper-lipoproteinaemia [5C80]
|
[13] |
Teriflunomide |
DMQ2FKJ
|
Major |
Additive immunosuppressive effects by the combination of Interferon Alfa-2a, Recombinant and Teriflunomide. |
Hyper-lipoproteinaemia [5C80]
|
[14] |
BMS-201038 |
DMQTAGO
|
Major |
Increased risk of hepatotoxicity by the combination of Interferon Alfa-2a, Recombinant and BMS-201038. |
Hyper-lipoproteinaemia [5C80]
|
[15] |
Polyethylene glycol |
DM4I1JP
|
Moderate |
Increased risk of lowers seizure threshold by the combination of Interferon Alfa-2a, Recombinant and Polyethylene glycol. |
Irritable bowel syndrome [DD91]
|
[16] |
Methotrexate |
DM2TEOL
|
Moderate |
Increased risk of hepatotoxicity by the combination of Interferon Alfa-2a, Recombinant and Methotrexate. |
Leukaemia [2A60-2B33]
|
[7] |
Denosumab |
DMNI0KO
|
Moderate |
Additive immunosuppressive effects by the combination of Interferon Alfa-2a, Recombinant and Denosumab. |
Low bone mass disorder [FB83]
|
[17] |
Calaspargase pegol |
DMQZBXI
|
Moderate |
Increased risk of hepatotoxicity by the combination of Interferon Alfa-2a, Recombinant and Calaspargase pegol. |
Malignant haematopoietic neoplasm [2B33]
|
[9] |
Cladribine |
DM3JDRP
|
Major |
Additive immunosuppressive effects by the combination of Interferon Alfa-2a, Recombinant and Cladribine. |
Mature B-cell leukaemia [2A82]
|
[7] |
Idelalisib |
DM602WT
|
Moderate |
Increased risk of hepatotoxicity by the combination of Interferon Alfa-2a, Recombinant and Idelalisib. |
Mature B-cell leukaemia [2A82]
|
[18] |
Alemtuzumab |
DMZL3IV
|
Moderate |
Additive immunosuppressive effects by the combination of Interferon Alfa-2a, Recombinant and Alemtuzumab. |
Mature B-cell leukaemia [2A82]
|
[19] |
Clofarabine |
DMCVJ86
|
Moderate |
Increased risk of hepatotoxicity by the combination of Interferon Alfa-2a, Recombinant and Clofarabine. |
Mature B-cell lymphoma [2A85]
|
[20] |
Thalidomide |
DM70BU5
|
Moderate |
Increased risk of peripheral neuropathy by the combination of Interferon Alfa-2a, Recombinant and Thalidomide. |
Multiple myeloma [2A83]
|
[12] |
Bortezomib |
DMNO38U
|
Moderate |
Increased risk of peripheral neuropathy by the combination of Interferon Alfa-2a, Recombinant and Bortezomib. |
Multiple myeloma [2A83]
|
[12] |
Interferon beta-1a |
DM1A6RV
|
Moderate |
Increased risk of hepatotoxicity by the combination of Interferon Alfa-2a, Recombinant and Interferon beta-1a. |
Multiple sclerosis [8A40]
|
[21] |
Tecfidera |
DM2OVDT
|
Moderate |
Additive immunosuppressive effects by the combination of Interferon Alfa-2a, Recombinant and Tecfidera. |
Multiple sclerosis [8A40]
|
[22] |
Siponimod |
DM2R86O
|
Major |
Additive immunosuppressive effects by the combination of Interferon Alfa-2a, Recombinant and Siponimod. |
Multiple sclerosis [8A40]
|
[23] |
Fingolimod |
DM5JVAN
|
Major |
Additive immunosuppressive effects by the combination of Interferon Alfa-2a, Recombinant and Fingolimod. |
Multiple sclerosis [8A40]
|
[24] |
Interferon beta-1b |
DMCN61Z
|
Moderate |
Increased risk of hepatotoxicity by the combination of Interferon Alfa-2a, Recombinant and Interferon beta-1b. |
Multiple sclerosis [8A40]
|
[21] |
Ocrelizumab |
DMEZ2KH
|
Moderate |
Additive immunosuppressive effects by the combination of Interferon Alfa-2a, Recombinant and Ocrelizumab. |
Multiple sclerosis [8A40]
|
[25] |
Ozanimod |
DMT6AM2
|
Major |
Additive immunosuppressive effects by the combination of Interferon Alfa-2a, Recombinant and Ozanimod. |
Multiple sclerosis [8A40]
|
[7] |
Omacetaxine mepesuccinate |
DMPU2WX
|
Moderate |
Additive immunosuppressive effects by the combination of Interferon Alfa-2a, Recombinant and Omacetaxine mepesuccinate. |
Myeloproliferative neoplasm [2A20]
|
[26] |
Bupropion |
DM5PCS7
|
Major |
Increased risk of lowers seizure threshold by the combination of Interferon Alfa-2a, Recombinant and Bupropion. |
Nicotine use disorder [6C4A]
|
[27] |
Tramadol |
DMRQD04
|
Major |
Increased risk of lowers seizure threshold by the combination of Interferon Alfa-2a, Recombinant and Tramadol. |
Pain [MG30-MG3Z]
|
[28] |
Rasagiline |
DM3WKQ4
|
Moderate |
Decreased metabolism of Interferon Alfa-2a, Recombinant caused by Rasagiline mediated inhibition of CYP450 enzyme. |
Parkinsonism [8A00]
|
[23] |
Ropinirole |
DMA6S1D
|
Moderate |
Decreased metabolism of Interferon Alfa-2a, Recombinant caused by Ropinirole mediated inhibition of CYP450 enzyme. |
Parkinsonism [8A00]
|
[29] |
Lindane |
DMB8CNL
|
Moderate |
Increased risk of lowers seizure threshold by the combination of Interferon Alfa-2a, Recombinant and Lindane. |
Pediculosis [1G00]
|
[30] |
Leflunomide |
DMR8ONJ
|
Major |
Increased risk of hepatotoxicity by the combination of Interferon Alfa-2a, Recombinant and Leflunomide. |
Rheumatoid arthritis [FA20]
|
[14] |
Asenapine |
DMSQZE2
|
Moderate |
Decreased metabolism of Interferon Alfa-2a, Recombinant caused by Asenapine mediated inhibition of CYP450 enzyme. |
Schizophrenia [6A20]
|
[31] |
Pimozide |
DMW83TP
|
Moderate |
Decreased metabolism of Interferon Alfa-2a, Recombinant caused by Pimozide mediated inhibition of CYP450 enzyme. |
Schizophrenia [6A20]
|
[32] |
Trabectedin |
DMG3Y89
|
Moderate |
Increased risk of hepatotoxicity by the combination of Interferon Alfa-2a, Recombinant and Trabectedin. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Naltrexone |
DMUL45H
|
Moderate |
Increased risk of hepatotoxicity by the combination of Interferon Alfa-2a, Recombinant and Naltrexone. |
Substance abuse [6C40]
|
[33] |
Anagrelide |
DMSQ8MD
|
Moderate |
Decreased metabolism of Interferon Alfa-2a, Recombinant caused by Anagrelide mediated inhibition of CYP450 enzyme. |
Thrombocytosis [3B63]
|
[34] |
Azathioprine |
DMMZSXQ
|
Moderate |
Additive immunosuppressive effects by the combination of Interferon Alfa-2a, Recombinant and Azathioprine. |
Transplant rejection [NE84]
|
[23] |
Ganciclovir |
DM1MBYQ
|
Moderate |
Additive myelosuppressive effects by the combination of Interferon Alfa-2a, Recombinant and Ganciclovir. |
Virus infection [1A24-1D9Z]
|
[23] |
Valganciclovir |
DMS2IUH
|
Moderate |
Additive myelosuppressive effects by the combination of Interferon Alfa-2a, Recombinant and Valganciclovir. |
Virus infection [1A24-1D9Z]
|
[23] |
----------- |
|
|
|
|
|